AI
Tuesday, November 11, 2014 11:42:19 AM
CTIX Rallies on Great News!
Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the "Guardian Angel of the Human Genome"
Confirmed by this PR: Cellceutix PR 11-11-14
Cellceutix has also recently been informed of additional research data from the Company’s Phase 1 trial of Kevetrin for solid tumors being conducted at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. The trial is currently enrolling patients in the ninth cohort. Preliminary data show that 50 percent of patients treated with Kevetrin through the eighth cohort demonstrated enhancement in p21 expression in peripheral blood cells, and that these observations appeared dose-related. The biomarker p21 is tightly controlled by the tumor suppressor protein p53, which is often referred to as the “Guardian Angel Gene” because of its crucial role in controlling cell mutations. Initial comparisons between early and latter cohorts support Cellceutix’s expectations that p53 activation is dependent on extent of exposure to Kevetrin. These results support the hypothesis that Kevetrin has pharmacological activity in patients
Dr Rally Monkey says: BOOM!
Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the "Guardian Angel of the Human Genome"
Confirmed by this PR: Cellceutix PR 11-11-14
Cellceutix has also recently been informed of additional research data from the Company’s Phase 1 trial of Kevetrin for solid tumors being conducted at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. The trial is currently enrolling patients in the ninth cohort. Preliminary data show that 50 percent of patients treated with Kevetrin through the eighth cohort demonstrated enhancement in p21 expression in peripheral blood cells, and that these observations appeared dose-related. The biomarker p21 is tightly controlled by the tumor suppressor protein p53, which is often referred to as the “Guardian Angel Gene” because of its crucial role in controlling cell mutations. Initial comparisons between early and latter cohorts support Cellceutix’s expectations that p53 activation is dependent on extent of exposure to Kevetrin. These results support the hypothesis that Kevetrin has pharmacological activity in patients
Dr Rally Monkey says: BOOM!
"Games are won by players who focus on the playing field -- not by those whose eyes are glued to the scoreboard." - Warren Buffett
